Danaher Corporation

The Beneish M-Score of -2.551 for 2024 sits below the -1.78 threshold, so it is not in the elevated manipulation-risk zone. A Beneish score is built from ratios of reported financial line items, such as receivables, gross margin and accruals, and is used to flag patterns that sometimes accompany earnings overstatement. A result below the threshold is a reassuring screen, not a clearance of the filings. The Altman Z-Score of 1.31 is in the distress zone, which in this model blends liquidity, retained earnings, profitability, market value and asset turnover into a bankruptcy-risk screen. For a company with $79.9 billion in total assets at September 26, 2025 and substantial operating cash flow, readers may want to weigh that screen against the cash generation data rather than treat it as a forecast. The operating cash flow to net income ratio of 1.72 for 2024 means operating cash flow exceeded reported net income. The Piotroski F-Score and Fog Index are not on file for this synthesis, so no values are given for them. The MD&A excerpt leans heavily on tariff and re-shoring risk, and the risk-factor text names Chinese local medical device policies as a concrete example. Readers may want to look at how nine-month comprehensive income of $5,045 million, compared with net earnings of $2,417 million, was driven largely by foreign currency translation adjustments of $2,406 million. They may also want to note the $3,088 million in cash used for share repurchases over the same nine months. Taken together, the filings show a business with growing sales and substantial cash generation, offset by lower net earnings and operating profit, higher debt, and a distress-zone Altman reading that deserves a closer look.

Catalyst.The 10-Q for the quarter ended September 26, 2025 shows third-quarter sales of $6,053 million, up from $5,798 million a year earlier, and nine-month sales of $17,730 million versus $17,337 million. Management's MD&A excerpt centers on tariffs and re-shoring policies, including Chinese government programs that promote local medical devices, and states that the risks identified could adversely affect the business. Nine-month operating profit fell to $3,188 million from $3,438 million. During the quarter the company repurchased 10,000,000 shares under its 2024 and 2025 programs, leaving 37,000,000 shares authorized for future repurchase.

Hidden risk.The most easily missed tension is between the strong 2024 cash figures and the trend beneath them. Operating cash flow was $6.69 billion in 2024, down from $8.52 billion in 2022, while net income fell from $7.21 billion in 2022 to $3.9 billion in 2024. Long-term debt rose to $16.83 billion at September 26, 2025 from $15.5 billion at year-end 2024, and impairment charges were $548 million for the nine months versus $222 million a year earlier. Cash and equivalents dropped to $1,528 million from $2,078 million. The Altman Z-Score of 1.31 falls in the distress zone, a screening result that calls for a closer read of the balance sheet.